Feasibility of ADC histogram analysis for predicting of postoperative recurrence in aggressive spinal tumors

ADC直方图分析预测侵袭性脊柱肿瘤术后复发的可行性

阅读:3

Abstract

BACKGROUND: Risk stratification of spinal tumors is a major unmet clinical need for personalized therapy. PURPOSE: To explore the feasibility of pretreatment whole-lesion apparent diffusion coefficient (ADC) histogram in predicting local recurrence of aggressive spinal tumors. METHODS: 119 aggressive spinal tumor patients (median age, 40; range, 13-74  years) confirmed by pathological findings with a mean follow-up of 36 months were enrolled and divided into the recurrence and non-recurrence group. The histogram metrics of whole-lesion, including the maximum, mean, kurtosis, skewness, entropy, and percentiles (10th, 25th, 50th, 75th, 95th) ADC values, were evaluated and take the average. Fractal dimension (FD) was assessed in the three orthogonal directions and take maximum. Clinical and general imaging features were used to construct an alternative prognostic model for comparison. Variables with statistical differences would be included in stepwise logistic regression analysis. RESULTS: As for the clinical model, Enneking staging (odds ratio [OR]: 3.572; P = 0.04) and vertebral compression (OR: 4.302; P = 0.002) were independent predictors of recurrence. There was no statistical difference in FD between the two groups (P = 0.623). Among the ADC histogram parameters compared, skewness, maximum, and mean ADC values were independent risk factors and constructed ADC histogram prediction models. The ADC histogram model (AUC = 0.871) and the combined model (AUC = 0.884) performed better than the clinical prediction model (AUC = 0.704) with P-values of 0.004 and 0.001, respectively. CONCLUSION: Prediction models based on the ADC histogram analysis might represent serviceable instruments for the aggressive spinal tumors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。